KCT0007598
Recruiting
未知
Biomarker Study of Immune Checkpoint Inhibitors in Metastatic Head and Neck Squamous Cell Carcinoma
ational Cancer Center0 sites50 target enrollmentTBD
ConditionsNeoplasms
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Neoplasms
- Sponsor
- ational Cancer Center
- Enrollment
- 50
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Metastatic HNSCC patients who are expected to undergo monotherapy of nivolumab or pembrolizumab
- •2\. Expected survival is at least 12 weeks
- •3\. Patient must provide informed consent.
Exclusion Criteria
- •1\. Patients with poor performance status (ECOG 3 or 4\), and with an expected survival of 12 weeks or shorter.
- •2\. Patients who were previously diagnosed with another type of malignancy within 5 years of study enrollment date.
- •3\. Previous treatment history with immune checkpoint inhibitors (including anti\-CTLA4 antibodies)
- •4\. Patients who do not consent to this study
- •5\. Patients who are not feasible to obtain study samples
- •6\. Patients who are not feasible for thorough communication
- •7\. Patients who do not consent to using their samples for subsequent research purposes
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer other than adenocarcinoma or squamous cell carcinoma: multicenter retrospective observational studyon-small cell lung cancer other than adenocarcinoma or squamous cell carcinomaJPRN-UMIN000037777Hamamatsu University School of Medicine60
Recruiting
Not Applicable
Cohort study of immune-checkpoint-inhibitor antibody treatment in non-small-cell lung cancernon-small-cell lung cancerJPRN-UMIN000020719Saitama Medical University International Medical Center100
Completed
Not Applicable
The usefulness of immune checkpoint inhibitors among lung cancer patients with driver gene mutantsung cancerJPRN-UMIN000040789Yokohama City University
Recruiting
Not Applicable
A real-world study of efficacy and safety of Immune check point inhibitors in patients with non-small cell lung cancer harboring driver oncogene excepting EGFRJPRN-UMIN000049022orth East Japan Study Group870
Active, not recruiting
Phase 2
Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial CarcinomaLocally Advanced Bladder Urothelial CarcinomaLocally Advanced Renal Pelvis Urothelial CarcinomaLocally Advanced Ureter Urothelial CarcinomaLocally Advanced Urethral Urothelial CarcinomaLocally Advanced Urothelial CarcinomaMetastatic Bladder Urothelial CarcinomaMetastatic Renal Pelvis Urothelial CarcinomaMetastatic Ureter Urothelial CarcinomaMetastatic Urethral Urothelial CarcinomaMetastatic Urothelial CarcinomaStage IV Bladder Cancer AJCC v8Stage IV Renal Pelvis Cancer AJCC v8Stage IV Ureter Cancer AJCC v8Stage IV Urethral Cancer AJCC v8NCT04848519Emory University6